Amorphous Solid Dispersions Patent - Intra-Cellular Therapies
Summary
USPTO published patent application US20260091032A1 by Intra-Cellular Therapies, Inc. for stable amorphous solid dispersions of a quinoxaline-derived compound with potential applications in neurological and metabolic disorders. The application, filed August 6, 2025, contains 29 CPC classifications spanning formulations, compounds, and therapeutic indications.
What changed
Intra-Cellular Therapies, Inc. filed patent application US20260091032A1 covering new, stable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, along with manufacturing methods and pharmaceutical compositions. The compound targets multiple therapeutic areas including metabolic disorders (A61P 3/04), neurological conditions (A61P 25/06, 25/18, 25/22, 25/24, 25/28), and various CNS applications.
This publication is informational for competitors, investors, and IP professionals tracking pharmaceutical development. No immediate compliance action is required. Companies developing similar CNS or metabolic therapies should review the claims for potential freedom-to-operate considerations. The patent application does not create regulatory obligations but may inform competitive landscape analysis in the pharmaceutical sector.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AMORPHOUS SOLID DISPERSIONS
Application US20260091032A1 Kind: A1 Apr 02, 2026
Assignee
INTRA-CELLULAR THERAPIES, INC.
Inventors
Peng Li
Abstract
The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
CPC Classifications
A61K 31/4985 A61K 9/0019 A61K 9/0024 A61K 9/0053 A61K 9/1617 A61K 9/1635 A61K 9/1641 A61K 9/1652 A61K 9/2013 A61K 9/2027 A61K 9/2031 A61K 9/2054 A61K 9/4858 A61K 9/4866 A61K 47/38 A61P 3/04 A61P 25/06 A61P 25/18 A61P 25/22 A61P 25/24 A61P 25/28 A61K 9/10 C07D 471/16
Filing Date
2025-08-06
Application No.
19292836
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.